AI English summary of an SEC filing — figures as filed
Incyte INCYIncyte said total GAAP revenues for Q4 2024 were $1,178,698 thousand, up 16%, compared with the same quarter in the prior year, and full-year total GAAP revenues were $4,241,217 thousand, up 15%, compared with the prior year.
Key points
AI summaryIncyte said total GAAP revenues for Q4 2024 were $1,178,698 thousand, up 16%, compared with the same quarter in the prior year, and full-year total GAAP revenues were $4,241,217 thousand, up 15%, compared with the prior year.
The company said Jakafi net product revenues for Q4 2024 were $773 million, up 11%, and Opzelura net product revenues were $162 million, up 48%, compared with the same quarter in the prior year. For the full year, Jakafi net product revenues were $2.79 billion, up 8%, and Opzelura net product revenues were $508 million, up 50%, compared with the prior year.
Incyte said full-year 2024 GAAP operating income decreased 90% compared with the prior year, citing as factors expense relating to IPR&D assets acquired in the Escient acquisition of $679.4 million, Escient acquisition related compensation expense and severance payments of $38.0 million, and a milestone payment to MacroGenics of $100.0 million.
The company said cash, cash equivalents and marketable securities decreased from $3.7 billion at the end of 2023 to $2.2 billion at the end of 2024, citing as principal factors a $2.0 billion share repurchase completed in June 2024 and total cash consideration paid to Escient shareholders of $783 million.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Q4 2024 and Full-Year Total GAAP Revenues
Incyte said total GAAP revenues for Q4 2024 were $1,178,698 thousand, up 16%, compared with the same quarter in the prior year, and full-year total GAAP revenues were $4,241,217 thousand, up 15%, compared with the prior year.
Source · Based on the filing body and exhibits
Jakafi and Opzelura Net Product Revenues
The company said Jakafi net product revenues for Q4 2024 were $773 million, up 11%, and Opzelura net product revenues were $162 million, up 48%, compared with the same quarter in the prior year. For the full year, Jakafi net product revenues were $2.79 billion, up 8%, and Opzelura net product revenues were $508 million, up 50%, compared with the prior year.
Source · Based on the filing body and exhibits
Full-Year Operating Income Decline and Escient-Related Expenses
Incyte said full-year 2024 GAAP operating income decreased 90% compared with the prior year, citing as factors expense relating to IPR&D assets acquired in the Escient acquisition of $679.4 million, Escient acquisition related compensation expense and severance payments of $38.0 million, and a milestone payment to MacroGenics of $100.0 million.
Source · Based on the filing body and exhibits
Cash and Marketable Securities Balance Decrease
The company said cash, cash equivalents and marketable securities decreased from $3.7 billion at the end of 2023 to $2.2 billion at the end of 2024, citing as principal factors a $2.0 billion share repurchase completed in June 2024 and total cash consideration paid to Escient shareholders of $783 million.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…